H.C. Wainwright lowered the firm’s price target on Equillium to $5.50 from $20 and keeps a Buy rating on the shares. The target reduction is based on the elimination of future itolizumab sales from the model, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EQ: